A new topical treatment using visible light to activate a plant-derived compound has demonstrated superior results compared to one of the most widely prescribed drugs for early-stage skin lymphoma, offering patients a safer alternative with fewer adverse reactions. In a comparative clinical trial, 60% of patients treated with HyBryte (synthetic hypericin) achieved significant improvement in their skin lesions after 12 weeks, compared to only 20% of those receiving Valchlor (mechlorethamine), the standard topical chemotherapy .

How Does HyBryte Work Differently From Standard Treatments?

HyBryte represents a fundamentally different approach to treating cutaneous T-cell lymphoma (CTCL), a rare blood cancer that affects the skin. Rather than using DNA-damaging chemotherapy drugs, HyBryte combines a naturally derived photosensitizer called synthetic hypericin with visible light activation. Here's how the treatment works:

• Topical Application: The synthetic hypericin is applied directly to affected skin lesions, where it is absorbed by malignant T-cells.
• Light Activation: Approximately 24 hours after application, the lesions are exposed to safe, visible light in the red-yellow spectrum, which activates the hypericin and triggers cell death in the cancer cells.
• Deep Penetration: Unlike ultraviolet light used in traditional phototherapy, visible light penetrates more deeply into the skin, potentially treating thicker plaques and deeper lesions.
• No Secondary Cancer Risk: Because HyBryte avoids DNA-damaging drugs and ultraviolet exposure, it eliminates the risk of secondary malignancies, including melanoma, that can develop from traditional treatments.

What Did the Comparative Study Actually Show?

The recently published comparative study, which appeared in the peer-reviewed journal Oncology and Therapy, enrolled a small group of patients with early-stage CTCL to directly compare HyBryte against Valchlor over a 12-week treatment period . The results were striking in favor of the new therapy. Among HyBryte patients, 60% met the prospectively defined measure of treatment success, defined as at least a 50% improvement in their cumulative mCAILS (modified Composite Assessment of Index Lesion Severity) score compared to baseline. In contrast, only 20% of Valchlor patients achieved this same level of improvement.

The average cumulative improvement in lesion severity was 52.5% for HyBryte patients versus 34.7% for those receiving Valchlor, a meaningful difference in real-world outcomes . Notably, of the HyBryte patients who did not achieve the primary treatment success threshold, both still experienced substantial improvement of at least 30% in their lesion scores. The Valchlor group showed more variable results, with one patient actually worsening and withdrawing from the study entirely.

"Despite the small study sample size and a randomization that lead to the HyBryte group having patients with more extensive disease, HyBryte performed well and the results are consistent with previous studies demonstrating its rapid onset of action and benign safety profile compared to one of the most widely prescribed approved drugs for early-stage CTCL," stated Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for the comparability study.

Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group

Why Is the Safety Profile Such a Game-Changer?

Perhaps the most compelling finding from this trial involves tolerability and side effects. All patients who received HyBryte tolerated the treatment well with no adverse events directly related to the therapy. In stark contrast, 60% of Valchlor patients experienced at least one adverse event related to the chemotherapy, including rashes, application site sensitivity, allergic contact dermatitis, and general dermatitis . The consequences were serious enough that one Valchlor patient required permanent discontinuation of treatment, another needed temporary interruption, and a third required steroid treatment to manage the allergic reaction.

This safety advantage is particularly important because patients with CTCL often require long-term or repeated treatment courses. A therapy that patients can tolerate without significant skin reactions represents a substantial quality-of-life improvement. The fact that HyBryte is not systemically available, meaning it stays localized to the treated skin area and doesn't enter the bloodstream in meaningful amounts, further supports its favorable safety profile.

What Do Larger Clinical Trials Tell Us About HyBryte's Effectiveness?

The comparative study results align with findings from HyBryte's larger Phase 3 clinical trial, called the FLASH trial, which enrolled 169 patients with early-stage CTCL . In the first double-blind treatment cycle of that study, 16% of patients receiving HyBryte achieved at least a 50% reduction in their lesions after 8 weeks of twice-weekly treatment, compared to only 4% of those receiving placebo. This difference was statistically significant, meaning researchers had high confidence it wasn't due to chance.

When all patients in the FLASH trial were given the opportunity to receive HyBryte in the second treatment cycle, the response rate jumped to 40% among those who received 12 weeks of continuous treatment, compared to the initial 4% placebo response rate. This improvement was highly significant, suggesting that continued treatment leads to better outcomes. Notably, HyBryte proved equally effective against both plaque lesions and patch lesions, addressing a historical challenge in CTCL treatment where plaque lesions have been particularly difficult to treat.

In the optional third treatment cycle of the FLASH trial, 66% of patients chose to continue with HyBryte treatment, a strong indicator of patient satisfaction and confidence in the therapy. Among patients who received HyBryte throughout all three cycles, 49% demonstrated a positive treatment response, further supporting the drug's efficacy with extended use.

What's the Regulatory Status and What Comes Next?

HyBryte has received significant regulatory recognition that may accelerate its path to broader availability. The FDA has granted the treatment both orphan drug designation and fast track designation, designations reserved for therapies addressing serious rare diseases with limited treatment options . Additionally, the European Medicines Agency has granted orphan designation, indicating international recognition of the unmet medical need in CTCL treatment.

The publication of the comparative study results in a peer-reviewed journal represents an important milestone in establishing HyBryte's clinical evidence base. Oncology and Therapy, where the study was published, is an international open-access journal dedicated to publishing high-quality clinical research in oncology, ensuring that these findings are accessible to the medical community and patients seeking information about treatment options.

For patients with early-stage cutaneous T-cell lymphoma, HyBryte offers a promising alternative that combines superior efficacy with a dramatically improved safety profile compared to standard chemotherapy. The treatment's use of visible light rather than ultraviolet exposure, combined with its topical application and lack of systemic side effects, represents a meaningful advance in how dermatologic malignancies can be managed with reduced risk of long-term complications.